Patents by Inventor Penglie Zhang

Penglie Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10392405
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 27, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Viengkham Malathong, Jeffrey McMahon, Darren J. McMurtrie, Sreenivas Punna, Howard S. Roth, Rajinder Singh, Penglie Zhang
  • Patent number: 10370363
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: August 6, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali
  • Publication number: 20190209527
    Abstract: The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C—X—C motif chemokine receptor 2 (CXCR2) antagonist.
    Type: Application
    Filed: January 7, 2019
    Publication date: July 11, 2019
    Inventors: James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
  • Patent number: 10342781
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: July 9, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Pingchen Fan, Juan C. Jaen, Yandong Li, Jay P. Powers, Viengkham Malathong, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Patent number: 10336736
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: July 2, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Antoni Krasinski, Manmohan Reddy Leleti, Venkat Mali, Jeffrey McMahon, Rajinder Singh, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang
  • Publication number: 20190194208
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • Publication number: 20190192491
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Patent number: 10329314
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 25, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • Publication number: 20190167659
    Abstract: Compounds of formula (I) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:
    Type: Application
    Filed: October 3, 2018
    Publication date: June 6, 2019
    Inventors: Daniel DAIRAGHI, Dean R. DRAGOLI, Jaroslaw KALISIAK, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Rebecca M. LUI, Venkat Reddy MALI, Viengkham MALATHONG, Jay P. POWERS, Hiroko TANAKA, Joanne TAN, Matthew J. WALTERS, Ju YANG, Penglie ZHANG
  • Publication number: 20190144389
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 16, 2019
    Inventors: Pingchen FAN, Rebecca M. LUI, Venkat Reddy MALI, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • Patent number: 10287292
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 14, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Publication number: 20190135745
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: July 27, 2018
    Publication date: May 9, 2019
    Inventors: Christopher LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Yu WANG, Ju YANG, Penglie ZHANG
  • Patent number: 10266492
    Abstract: Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: April 23, 2019
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Jaroslaw Kalisiak, Antoni Krasinski, Rebecca M. Lui, Jay Powers, Sreenivas Punna, Hiroko Tanaka, Penglie Zhang
  • Publication number: 20190060304
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Application
    Filed: October 25, 2018
    Publication date: February 28, 2019
    Applicant: ChemoCentryx, Inc.
    Inventors: Xi CHEN, Junfa FAN, Pingchen FAN, Antoni KRASINSKI, Lianfa LI, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
  • Publication number: 20190048022
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I) or (II): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R, R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, R6c, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: August 7, 2018
    Publication date: February 14, 2019
    Inventors: Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
  • Publication number: 20190016709
    Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
    Type: Application
    Filed: March 7, 2018
    Publication date: January 17, 2019
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • Publication number: 20190010177
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 10, 2019
    Inventors: Pingchen FAN, Antoni KRASINSKI, Venkat Reddy MALI, Shichang MIAO, Sreenivas PUNNA, Yang SONG, Valentino J. STELLA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20180370967
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Rajinder SINGH, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • Publication number: 20180369213
    Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
    Type: Application
    Filed: February 20, 2018
    Publication date: December 27, 2018
    Inventors: Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Yandong LI, Jay P. POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
  • Publication number: 20180346471
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 6, 2018
    Inventors: Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Yibin ZENG, Penglie ZHANG